Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MPO | P05164 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ALPI | P09923 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | XIAP | P98170 | 1/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2574824 | 0.88 | KDM4E (0.50) | FOLH1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL28465292 | 0.86 | KDM4E (0.58) | FOLH1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL28900368 | 0.86 | KDM4E (0.58) | FOLH1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL19467885 | 0.86 | FOLH1 (0.49) | FOLH1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL4906029 | 0.84 | KDM4E (0.51) | FOLH1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL4906035 | 0.84 | KDM4E (0.51) | FOLH1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL28488206 | 0.81 | KDM4E (0.54) | FOLH1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL1509968 | 0.81 | KDM4E (0.54) | FOLH1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL28488664 | 0.81 | KDM4E (0.54) | FOLH1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL497627 | 0.79 | KDM4E (0.55) | FOLH1KDM4EMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897721-B2 | Cyclic peptide compositions for treatment of sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20100121027-A1 | Cyclic Peptide Compositions for Treatment of Sexual Dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-7473760-B2 | Cyclic peptide compositions for treatment of sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2009-01-06 | — | — | US | disclosed |
| US-7176279-B2 | Cyclic peptide compositions and methods for treatment of sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1667700-A2 | CYCLIC PEPTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF SEXUAL DYSFUNCTION | Palatin Technologies, Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20060111281-A1 | Cyclic peptide compositions for treatment of sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2006-05-25 | — | — | US | disclosed |
| WO-2005014617-A2 | CYCLIC PEPTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF SEXUAL DYSFUNCTION | PALATIN TECHNOLOGIES, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| US-20040138136-A1 | Cyclic peptide compositions and methods for treatment of sexual dysfunction | PALATIN TECHNOLOGIES, INC. | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111281-A1 | Cyclic peptide compositions for treatment of sexual dysfunction | VIP, GNRHR, NPR1 | FOLH1 350/4885KDM4E 3883/4885MEN1 653/4885 |
| US-20040138136-A1 | Cyclic peptide compositions and methods for treatment of sexual dysfunction | VIP, GNRHR, NGLY1 | FOLH1 185/4885KDM4E 4262/4885MEN1 1486/4885 |
| US-20100121027-A1 | Cyclic Peptide Compositions for Treatment of Sexual Dysfunction | VIP, GNRHR, NPR1 | FOLH1 350/4885KDM4E 3883/4885MEN1 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.